AUS
NZ
UK
CA
USA
IND
Highlights
- Biome Australia aims to significantly increase sales over the next three years.
- Anteris Technologies delays US IPO plans while progressing towards its goal.
- Artrya submits FDA application for its AI-based coronary disease detection product.
Biome Australia (ASX:BIO) has laid out ambitious plans to substantially increase its sales, targeting a cumulative revenue of $75-85 million within the next three years. This marks a significant leap from the cumulative $22.5 million achieved over the past three years. Biome aims to transform from a microcap company into a notable player in the rapidly growing supplement sector.
The company specializes in probiotics, microorganisms claimed to benefit gut health when ingested. Although the effectiveness of probiotics can vary, Biome's flagship Activated Probiotics range addresses a variety of health issues, including acne, eczema, irritable bowel syndrome, and cholesterol management.
This sales target is part of Biome's Vision 27 manifesto, introduced recently. The strategy includes expanding its distribution network from 5,000 outlets—such as Priceline and Terry White pharmacies—to 8,000 by the end of 2027. In the year ending June 30, Biome reported a revenue increase of 80%, totaling $13 million, with a net loss of $1.67 million, showing a 45% improvement.
Of the total revenue, $895,000 came from international sales in markets like the UK and Ireland, with further expansion planned in Canada, France, and the Benelux countries. Notably, Biome identified a significant opportunity, as approximately 330 million prescriptions are dispensed in Australia annually, presenting a potential market for activated probiotic products.
Despite facing competition from larger nutraceutical companies such as Blackmores, Biome stands out as a probiotic-focused enterprise on the ASX. The company has seen its shares quadruple in the past year, reflecting growing market confidence in its strategy and execution.
In related developments, Anteris Technologies (ASX:AVR) has postponed its Extraordinary General Meeting to approve its plans for a US listing and IPO. This change in timing is seen as a normal part of complex cross-border transactions. Anteris is developing a transcatheter heart valve aimed at treating aortic stenosis and is nearing the stage to start a pivotal phase III trial with the FDA.
Meanwhile, Artrya (ASX:AYA) has submitted an FDA application for its AI-based Salix Coronary Anatomy product, designed to detect coronary artery disease by identifying plaque build-up in arteries. This product is already approved for use in several regions, including Australia and Europe, and the FDA application is anticipated to streamline the sales process post-approval.
Lastly, Pacific Smiles (ASX:PSQ) is facing challenges with its ongoing takeover discussions. The board has rejected a recent offer from Beam Dental, citing that the proposal does not reflect the company’s stronger performance. The situation remains complex as shareholders express intentions to reject the offer, impacting the stock's performance.
